With the new Health and Care Bill edging ever closer to receiving Royal Assent, life sciences companies in the UK are preparing to navigate the most significant piece of NHS legislation in a decade.
The new bill, which is expected to come into force on 1st July, will see Clinical Commissioning Groups replaced with Integrated Care Systems (ICSs) as statutory bodies across England. These ICSs will be comprised of two parts – an integrated care board (ICB), which will be responsible for strategic planning and allocation decisions in the NHS, and an integrated care partnership (ICP), responsible for assembling system partners and developing an action plan for public health and social care needs across a designated geographical area.
However, while this dramatic shake-up of the UK Market Access environment aims to improve care for patients and providers for life science companies, this unfamiliar territory presents both opportunities and challenges. So, what are the key elements that decision-makers need to address in order to develop successful future strategies?
The webinar will also cover:
- Up to date analysis of political, economic, social, technological, environmental, and legal factors surrounding the new legislation
- Key issues keeping pharma and ICS awake at night
About the panel
Uday Bose, country managing director and head of human pharma, Boehringer Ingelheim. Uday Bose is a highly experienced and successful leader in the pharmaceutical industry within the human pharma sector, with over 25 years’ experience spanning general management, health economics, sales and marketing roles with National (UK/Ireland), Regional (EMEA) and Global accountability. He has significant speciality care experience, including all aspects of commercialisation for early and late stage assets including 15 launches across 6 products. Since November 2018, Uday has held the position of country managing director and head of human pharma for Boehringer Ingelheim UK & Ireland. In May 2020, Uday was appointed to the Association of the British Pharmaceutical Industry (ABPI) Board of Management. He is also Chair of the European Medicines Group.
Matthias Winker, head of Integrated Care System strategy, Buckinghamshire, Oxfordshire and Berkshire West. Matthias is an internationally experienced professional at a senior level in the healthcare industry with a focus to create value for public and private provider organisations, commissioner, life science companies, governments and authorities. He worked in the NHS on provider corporate and clinical services strategies. In his current role, Matthias heads the strategy function of an Integrated Care System and works on the future positioning of the ICS to deliver better outcomes, improve population health and drive economic and social growth throughout the health and life sciences eco system. He holds a Master’s degree in health economics and is an alumni of the Henley Business School.
Jim McArdle, commercial director, Interface Clinical Services, IQVIA. After qualifying as a pharmacist, Jim worked across many sectors of pharmacy both in the UK and internationally. In 2006, Jim joined Interface Clinical Services as commercial director, responsible for strategy and growth, and was a key factor in the success of the organisation. A passionate proponent of the role of clinical pharmacists, harnessing data to inform clinical and commissioning decisions, and patient centricity, Jim is viewed as a true innovator in healthcare. He has led on many projects designed to improve the lives and wellbeing of patients across primary and secondary care and recognizes the value in collaborative working between the NHS and life science sector to bring innovative solutions to health economies and to patients. Jim has a BSc in Pharmacy from LJMU and a Masters in Business Administration (MBA) from the University of Liverpool.
Dr Paul Tunnah, chief content officer and managing director UK, Healthware (moderator). Alongside his work as a recognised author, speaker, moderator and industry advisor, he founded the industry-leading publication pharmaphorum in 2009. Dr Tunnah also holds a BA in Biochemistry and DPhil in Biological Sciences from Oxford University, where his work focused on identification of novel anticancer therapies.
The post ICSs – an opportunity to improve Patient & Market Access at a local level appeared first on .
